NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
Status:
Terminated
Trial end date:
2020-03-19
Target enrollment:
Participant gender:
Summary
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with
either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will
receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both
groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a
dose escalation and a subsequent dose expansion part.